Great point golfyeti. There is theory and reality and then there is accounting rules. If/ when we pass this BoM trial our probability of success should go up to about 84%. At that point the accounting rules will make that liability seem quite ugly but in reality it doesn't really matter to any RVX sharehold except possibly one, Hepalink. Since they own as great a percentage of RVX as they do I believe they have to recognize their proportionate share of that accounting loss on their financials. As for the rest of us, who really cares.

If/when we pass BoM someone else will be taking this product to the market so that accounting liability will go with that transaction and the RVX shareholders will hopefully walk away with pockets full of money. The good news for the Zenith shareholders is to look at the potential royalties that we can look forward to once apabetalone hits the market. This accounting situation will likely have zero effect on any negotiations what's so ever. Now before anyone says; how can it have no effect, I will quantify the statement and say it is more of the normal practice of valuing drugs that get acquired. We have seen many many examples of companies that have been bought out on this board with royalties in place. It actually seems like the norm and not the exception to have some kind of royalty arrangement in place when a drug finally does get acquired by a BP.

chicagoest - Thanks for bringing this accounting situation to the boards attention as many who read this board likely didn't understand what it really meant.

tada